Arbutus Biopharma Corp (NASDAQ:ABUS)
| 2.50 Delayed Data As of Aug 12 |  +0.03 / +1.21%Today’s Change | 1.93 Today|||52-Week Range 6.50 | -35.73% Year-to-Date |
Latest ABUS News | Press Releases
| Arbutus Biopharma (ABUS) Q2 2022 Earnings Call Transcript Aug 04 / MotleyFool.com - Paid Partner Content | Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates Aug 04 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 2.47 |
| Today’s open | 2.46 |
| Day’s range | 2.46 - 2.54 |
| Volume | 23,044 |
| Average volume (3 months) | 1,084,364 |
| Market cap | $374.9M |
Data as of 3:59pm ET, 08/12/2022
Growth & Valuation
| Earnings growth (last year) | +16.84% |
| Earnings growth (this year) | +45.06% |
| Earnings growth (next 5 years) | +3.00% |
| Revenue growth (last year) | +58.92% |
| P/E ratio | NM |
| Price/Sales | 37.61 |
| Price/Book | 2.14 |
Competitors
| ---- | ||
| --Cassiopea SpA | 0.00 | 0.00% |
| EYPTEyePoint Pharmaceuti... | -0.07 | -0.63% |
| STROSutro Biopharma Inc | +0.29 | +4.26% |
Data as of 3:59pm ET, 08/12/2022
Financials
| Next reporting date | November 9, 2022 |
| EPS forecast (this quarter) | -$0.13 |
| Annual revenue (last year) | $11.0M |
| Annual profit (last year) | -$76.2M |
| Net profit margin | -693.91% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Warminster, Pennsylvania |
Forecasts
